Company intelligence / Profile preview

NFL Biosciences

Castelnau-le-Lez, Occitanie, Francenflbiosciences.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

NFL Biosciences’ lead candidate, NFL‑101—a nicotine-free tobacco leaf protein extract for smoking cessation—is in Phase 2b/Phase III clinical trials. Early results and ongoing studies aim to demonstrate efficacy as a botanical alternative for nicotine withdrawal. Additional pipeline programs target cannabis and alcohol addictions at the preclinical stage

Therapeutic areas: Psychiatry
Modalities: Botanical drugs (plant-derived extracts)natural products
Industry: Biotech

Drug pipeline

4 assets

nfl-101

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed yet; company aims to partner with pharma companies for commercialization in the future

Beyond the preview

Go deeper on NFL Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NFL Biosciences.

Explore the full profile